ANGLE PLC (LON:AGL, OTCQX:ANPCY) said its Parsortix technology for harvesting circulating tumour cells had shown some early promise in helping researchers identify women with malignant ovarian tumours.
Parsortix is being used in two separate trials – one in Europe, the other in the US. Both are recruiting 200 patients and the update from the med-tech firm comes from analysis of very early data from both studies.
The results show the ANGLE-developed system could accurately differentiate between women with a malignant pelvic mass and those with benign tumours.
Parsortix could also have the additional benefit of providing valuable gene expression information, which could help further refine treatment decisions.
“Such data, if confirmed over the remaining samples, would represent an advantage over currently available clinical risk assessment tools,” said ANGLE in a stock exchange statement.
The studies are being carried out by Dr Robert Zeillinger at the Medical University of Vienna and Dr Richard Moore at the University of Rochester Medical Center, Wilmot Cancer Institute.
So far data has been obtained from the first 50 patients enrolled in each study. Headline results from the completed trials will be available in the second quarter.
The Partsortix device could potentially save time and money in being able to tell whether a mass is benign or malignant in advance of surgery.
ANGLE estimates the addressable global market for the pre-surgical assessment of ovarian cancer risk could be in excess of £300mln a year.
Founder and chief executive Andrew Newland said: "The interim data evaluation supports the potential for ANGLE's first clinical application to out-perform standard of care for the detection of ovarian cancer, particularly in relation to specificity avoiding false positives.
“Additionally there is an opportunity using Parsortix to obtain molecular information to guide therapy prior to surgery, which is not possible with existing approaches."
Separately, ANGLE delivered its interim results statement Thursday, which charted the significant progress made by the company.
This included “extensive work” towards Parsortix’s clearance in metastatic breast cancer from the US Food & Drug Administration (FDA). Analytical study work is under way and making good headway.
Meanwhile, a clinical study plan, involving 200 metastatic breast cancer patients and 200 healthy volunteers, has been submitted to the scientific review committees at three world-leading US cancer centres for formal review.
Completion of analytical and clinical studies is expected in 2017 to enable a submission to the FDA.
There’s also been an increase in research use of Partsortix. For instance, the Cancer Research UK Manchester Institute has selected the technology for routine use in clinical trials and has processed 1,100 patient samples in 16 clinical trials.
Meanwhile, the Medical University of Vienna has incorporated Parsortix into the Gannet53 ovarian cancer trial and has processed over 400 patient samples.
There’s also a growing body of published evidence, from internationally-recognised cancer centres that validates Parsortix as a potent and cutting edge liquid biopsy solution.
As is common with companies at this pre-commercial stage of development, ANGLE was lossmaking (to the tune of £2.7mln in the six months ended October 31). More importantly, it sits on solid financial foundations with £9.7mln in the bank as at the period end.